Patent intelligence · US
US 8252926
Process for the preparation of imatinib base
Process for the preparation of imatinib base
Patent details — US 8252926
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 28, 2012
- Expiration
- Aug 23, 2032
- Applicant
- Mustafa Nevzat llaç Sanayii A.S.
- Claims
- 16
- CPC classes
- A61P, A61P35/00
Quick answer
US 8252926 (Process for the preparation of imatinib base) is held by Mustafa Nevzat llaç Sanayii A.S.. Status: granted. Granted Aug 28, 2012. Expires Aug 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mustafa Nevzat llaç Sanayii A.S.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P35/00
More from Mustafa Nevzat llaç Sanayii A.S.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Related coverage
Frequently asked questions
What is US patent 8252926?
US 8252926 (Process for the preparation of imatinib base) is held by Mustafa Nevzat llaç Sanayii A.S.. Status: granted. Granted Aug 28, 2012. Expires Aug 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8252926?
Mustafa Nevzat llaç Sanayii A.S. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 8252926 expire?
Our index shows an expiration date of Aug 23, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.